MAP2K7 and metastatic melanoma: In one study regarding the treatment of BRAF-induced metastatic melanoma, patients treated with Dabrafenib plus Trametinib (BRAF therapy + MEK inhibitor) had reduced their risk of death by 31% when compared to Vemurafenib alone (BRAF inhibitor), and prolonged free survival was significantly higher with the combined therapy when compared to Dabrafenib plus placebo [63].